Human Genome Sciences Announces Pricing of Public Offering of Common Stock

Tue Jul 28, 2009 7:45pm EDT

* Reuters is not responsible for the content in this press release.

ROCKVILLE, Md., July 28  /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
(Nasdaq: HGSI) today announced the pricing of its underwritten public offering
of 23,215,000 newly issued shares of its common stock at a price to the public
of $14.00 per share. The size of the offering was increased from the
originally announced 18,000,000 shares. The Company also granted the
underwriters a 30-day option to purchase up to an additional 3,482,250 shares
of the Company's common stock.  The offering is expected to close on August 3,
2009, subject to customary closing conditions.  The Company anticipates net
proceeds from the offering of approximately $310 million.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint
book-running managers for the offering.

The shares will be issued pursuant to an effective shelf registration
statement.  This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy any securities of Human Genome Sciences, Inc.,
nor shall there be any sale of securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or
jurisdiction.  When available, a copy of the prospectus supplement and
accompanying prospectus relating to the offering may be obtained from Goldman,
Sachs & Co., at 85 Broad Street, New York, New York 10004, Attention:
Prospectus Department, Toll-Free 1-866-471-2526, or by email at
prospectus-ny@ny.email.gs.com and Citigroup Global Markets Inc. at Brooklyn
Army Terminal, 140 58(th) Street, 8(th) Floor, Brooklyn, NY 11220, Attention:
Prospectus Department, 800-831-9146.

About Human Genome Sciences 

Human Genome Sciences is a commercially focused biopharmaceutical company.  In
the first half of 2009, HGS achieved its first product revenues of $162.7
million when we delivered raxibacumab (ABthrax(TM)) to the U.S. Strategic
National Stockpile for the treatment of inhalation anthrax. HGS has two other
products in late-stage clinical development:  ZALBIN(TM) (formerly
Albuferon((R))) for chronic hepatitis C and BENLYSTA((TM)) (formerly
LymphoStat-B((R))) for systemic lupus erythematosus.

For more information about HGS, please visit the Company's web site at
www.hgsi.com.  Health professionals and patients interested in clinical trials
of HGS products may inquire via e-mail to medinfo@hgsi.com or by calling HGS
at (877) 822-8472.

HGS, Human Genome Sciences, ABthrax, Albuferon, BENLYSTA, LymphoStat-B, and
ZALBIN are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement 

This announcement contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking statements
are based on Human Genome Sciences' current intent, belief and expectations.
These statements are not guarantees of future performance and are subject to
certain risks and uncertainties that are difficult to predict. Actual results
may differ materially from these forward-looking statements because of Human
Genome Sciences' unproven business model, its dependence on new technologies,
the uncertainty and timing of clinical trials, Human Genome Sciences' ability
to develop and commercialize products, its dependence on collaborators for
services and revenue, its substantial indebtedness and lease obligations, its
changing requirements and costs associated with facilities, intense
competition, the uncertainty of patent and intellectual property protection,
Human Genome Sciences' dependence on key management and key suppliers, the
uncertainty of regulation of products, the impact of future alliances or
transactions and other risks described in the Company's filings with the SEC. 
Existing and prospective investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of today's date. 
Human Genome Sciences undertakes no obligation to update or revise the
information contained in this announcement whether as a result of new
information, future events or circumstances or otherwise.

SOURCE  Human Genome Sciences, Inc.

Media, Jerry Parrott, Vice President, Corporate Communications,
+1-301-315-2777, or Investors, Peter Vozzo, Senior Director, Investor
Relations, +1-301-251-6003, both of Human Genome Sciences
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.